Thierry Andr é, MD, on Interim Results from the Phase III Keynote-177 Study
The findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Thierry Andr é, MD Source Type: news
Benoit You, MD, PhD, on the use of Avelumab to Treat Patients With Gestational Trophoblastic Tumors
The expert from the Centre Hospitalier Lyon-Sud discussed the results of a phase II study of avelumab for patients with GTT who were resistant to chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Benoit You, MD, PhD Source Type: news
AMG 330 Appears Safe, Tolerable in Relapsed/Refractory Acute Myeloid Leukemia
The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Kelly Morgan, MS, CGC, on Exploring Targeted Testing for the Ashkenazi Jewish BRCA Mutation
The MSK expert discussed the need for targeted testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kelly Morgan, MS, CGC Source Type: news
Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive Ovarian Cancer
A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Apalutimide Plus ADT Improves Survival in Nonmetastatic Castration-Resistant Prostate Cancer
Final data analysis of SPARTAN trial demonstrates large benefit in overall survival when compared with ADT plus placebo. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news
KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCL
When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Ryan McDonald Source Type: news
Courtney DiNardo, MD, on Need for Improved, Effective Regimens in IDH1-Positive AML
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Courtney DiNardo, MD Source Type: news
Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC
Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Phase III HERO Trial Finds Relugolix to be Superior to Leuprolide in Prostate Cancer
The results suggested the potential for this agent to become a new standard for T-suppression in this patient population. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma
Results of KEYNOTE-204 supports pembrolizumab as new standard of care for patients with classical Hodgkin Lymphoma who have relapsed after autologous stem cell transplant or are ineligible for autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news
Off-the-Shelf CAR T-Cell Therapy Shows Promise in Relapsed/Refractory B-Cell Lymphomas
The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Conor Killmurray Source Type: news
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer
A study presented at the 2020 ASCO Scientific Program combining mirvetuximab soravtansine with bevacizumab to treat platinum-agnostic ovarian cancer demonstrated an encouraging overall response rate and tolerability profile regardless of platinum status. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
